Difference between revisions of "Maple Syrup Urine Disease 2012"
(→Tasks) |
m (moved Maple Syrup Urine Disease to Maple Syrup Urine Disease 2012) |
||
| (11 intermediate revisions by 2 users not shown) | |||
| Line 114: | Line 114: | ||
| − | + | = Tasks = |
|
*[[Task 2: Multiple Sequence Alignment]] |
*[[Task 2: Multiple Sequence Alignment]] |
||
| − | *[[Task 3: |
+ | *[[Task 3: odba_human Sequence-based predictions]] |
*[[Task 4: Homology-based structure prediction]] |
*[[Task 4: Homology-based structure prediction]] |
||
*[[Task 5: Researching SNPs]] |
*[[Task 5: Researching SNPs]] |
||
| + | *[[Task 6: MSUD - Sequence-based mutation analysis]] |
||
| + | *[[Task 7: MSUD - Structure-based mutation analysis]] |
||
| + | *[[Task 8: MSUD - Molecular Dynamics Simulations]] |
||
| + | *[[Task 9: MSUD - Normal Mode Analysis]] |
||
| + | |||
| + | = Final Report = |
||
| + | The final report will be uploaded here once it is finished. |
||
Latest revision as of 13:22, 21 February 2013
Contents
Summary
Maple Syrup Urine Disease is an autosomal recessive disorder, which affects the degradation of the branched chain amino acids(BCAA) Leu, Ile, Val. The name comes from a maple syrup odor of affected patients urine, which is caused by high levels of sotolon [1] in the patient's urine. A world wide study in 2001 described a frequency of 1 affected per 185.000 births.
Phenotype
Symptoms shown almost immediately after birth include poor feeding, vomiting, dehydration, lethargy, hypotonia, seizures, hypoglycaemia, ketoacidosis, opisthotonus, pancreatitis, coma and neurological decline [2]. Within a week after birth the neurological damage is irreversible. The most prominent symptom is probably the sweet smelling urine, that is often characterized as maple syrup like, hence the name. In Mediterranean or eastern countries, where maple syrup is rather uncommon, it is reminiscent as fenugreek[3].
MSUD is classified in four categories, according to the amount and type of remaining enzyme activity[4]:
- Classic severe MSUD. The most common variant. Remaining enzymatic activity below 2%. Symptoms usually show within the first few days of life. Severely restricted diet necessary.
- Intermediate MSUD. Remaining enzymatic activity usually between 3-8%. Somewhat better branched chain amino acid tolerance, when healthy. During illness tolerance is usually reduced. Treatment similar to classic MSUD.
- Intermittent MSUD. Remaining enzymatic activity usually between 8-15%. Symptoms only show during episodes (mostly caused by illness or huge protein intake).
- Thiamine-responsive MSUD. Medication with large amounts of Thiamine restores enzymatic function. Only moderate diet necessary. Unfortunately not very common variant.
Diagnosis
Fortunately MSUD can be diagnosed both prenatal (by detection of enzymatic deficiency in the aminon) or by checking the Leu-levels in blood or urine during newborn screening.
Treatment
- Patients with Thiamine-responsive MSUD can be treated with aforementioned drug are able to process branched chain amino acids. There is no, to very little dietary restriction and observation necessary for Thiamine-responsive patients.
- Other forms of MSUD need to uphold a life long diet and observation to avoid to high BCAA levels.
Biochemical disease mechanism
MSUD affects a protein called branched-chain alpha-keto acid dehydrogenase complex (BCKDHC), which is involved in the degradation of branched amino acids (Val, Leu, Ile). The inability of degrading these amino acids, leads to an enrichment of those and their toxic byproducts in the body. BCKDHC consists of four subunits:
| subunit | name | chromosomal gene location | MSUD-type |
|---|---|---|---|
| BCKDHA | Branched chain keto acid dehydrogenase E1, alpha polypeptide | 19q13.1-q13.2 | 1a |
| BCKDHB | branched chain keto acid dehydrogenase E1, beta polypeptide | 6q14.1 | 1b |
| DBT | Dihydrolipoamide branched chain transacylase E2 | 1p31 | 1/2 |
| DLD | dihydrolipoamide dehydrogenase | 7q31-q32 | 3 |
Mutations
Reference sequence
Mutated sequence
- Nonsense/missense mutated sequence BCKDHA
>sp|P12694|ODBA_HUMAN 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial OS=Homo sapiens GN=BCKDHA PE=1 SV=2 MAVAIAAARVWRLNRGLSQAALLLLRQPGARGLARSHPPRQQQQFSSLDDKPQFPGASAE FIDKLEFIQPNVISGIPIYRVMDRQGQIINPSEDPHLPKEKVLKLYKSMTLLNTMDRILY ESQRQGRISFYMTNYGEEGTHVGSAAALDNMNLVFGQYWEAGVLMNQDYPLELFMAQCYG NISDLGKGRKMPVHYGCKERHFVTISSPLATQTPQVVGAAYAAKRANANRVVICYFGEGA ASEGDAHASFNFTATLEYPIIFFWWNSGYAISTPTSEQYRGDDIPA|GPRYGIMSIC/HVD SNAVFAVYNARKEA|RRAVAENQPFLTKTMTYRIGHHSTSDDSSAYHSVDEVNYWDKQDH PISWLRHYLLSQGWWDEEQEKAWRKQSRRKVMEAFEQAERKPKPNPNLLCSDMH/CQEMPA QLRKQQESLARHLQTYGEHNPLDHFDK
- Nonsense/missense mutated sequence BCKDHB
>sp|P21953|ODBB_HUMAN 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial OS=Homo sapiens GN=BCKDHB PE=1 SV=2 MAVVAAAAGWLLRLRAAGAEGHWRRLPGAGLARGFLHPAATVEDAAQRRQVAHFTFQPDP EPREYGQTQKMNLFQSVTSALDNSLAKDPTAVIFGEDVAFGGVFRCTVGL|DKYGKDRGF NTLLCEQGIGGFGIRIVVTGATAIAEIQFADYIFPAFDKIVN|AAKYH/CYRSWDLFYCGS LTIPSPWGCDGHGALYHSQSAEAFFAR/YCPGIKVVKPGSPFQARGLLLSCIEDKNPCIFF EP|ILHRAAAEEAPIEPYNIPLSQAEVI|EGSDVTLVACSTQVHAI|EVASMAKEKLGVS CEVIDLRTIIPWDVDTICKSVIKTG|LLISHEAPLTGGFALKISSTVQEECFLNLEALIS RVCGYDTPFPHIF|PFYIPDKWKC|DALRKMINY
- Nonsense/missense mutated sequence DBT (leading to type 1)
>sp|P11182|ODB2_HUMAN Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial OS=Homo sapiens GN=DBT PE=1 SV=3 MAAVRMLRTWSRNAGKLICVRYFQTCGNVHVLKPNYVCFFGYPSFKYSHPHHFLKTTAAL RGQVVQFKLSDIGEGIREVTVKEWYVKEGDTVSQFDSMCEVQSDKASVTITSRYDGVIKK LYYNLDDIAYVRKPLVDTETEALKDSEEDVVETPAVSHDEHTHQEIKGRKTLATPAVRRL AMENNIKLSEVVG|GKDGRILKEDILNYLEKQTGAILPPSPKV|IMPPPPKPKDMTVPIL VSKPPVFTGKDKTEPIKGFQKATVKTMSAALKIPHCGYCDEIDLTELVKLREELKPIAFA RGIKLSSMPFFLNAASLGLLQFPILNASVDENCQNITYKASNNIGIAMDTEQGLIVPNVK NVQICSIFDIATELNRLQKLGSVSQLSTTGLTGGTFTPSNIGSIGGTFAKQVIMPPEVAI GALGSIKANPRFNQKGEVYKAQIMNMSWSDDRRVIDGATMSPFSNLWKSYLENPAFMLLD LK
- Nonsense/missense mutated sequence DBT (leading to type 2)
>sp|P11182|ODB2_HUMAN Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial OS=Homo sapiens GN=DBT PE=1 SV=3 MAAVRMLRTWSRNAGKLICVRYFQTCGNVHVLKPNYVCFFGYPSFKYSHPHHFLKTTAAL RGQVVQFKLSDIGEGIREVTVKEWYVKEGDTVSQFDSMCEVQSDKASVTITSRYDGVIKK LYYNLDDIAYVRKPLVDTETEALKDSEEDVVETPAVSHDEHTHQEIKGRKTLATPAVRRL AMENNIKLSEVVG|GKDGRILKEDILNYLEKQTGAILPPSPKV|IMPPPPKPKDMTVPIL VSKPPVFTGKDKTEPIKGFQKATVKTMSAALKIPHCGYCDEIDLTELVKLREELKPIAFA RGIKLSSMPFFLNAASLGLLQFPILNASVDENCQNITYKASNNIGIAMDTEQGLIVPNVK NVQICSIFDIATELNRLQKLGSVSQLSTTGLTGGTFTPSNIGSIGGTFAKQVIMPPEVAI GALGSIKANPRFNQKGEVYKAQIMNMSWSDDRRVIDGATMSPFSNLWKSYLENPAFMLLD LK
- Nonsense/missense mutated sequence DLD
>sp|P09622|DLDH_HUMAN Dihydrolipoyl dehydrogenase, mitochondrial OS=Homo sapiens GN=DLD PE=1 SV=2 MQSWSRVYCSLAKRGHFNRISHGLQGLSAVPLRTYADQPIDADVTVIGSGPGGYVAAIKA AQLGFKTVCIEENETLGGTCLNVGCIPSKALLNNSHYYHMAHGTDFASRGIEMSEVRLNL DKMMEQKSTAVKALTGGIAHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNIL IATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELCSVWQRLGADVT AVEFLGHVGGVGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSIEAASGGK AEVITCDVLLVCIGRRPFTKNLGLEELGIEVDPRGRIPVNTRFQTKIPNIYAIGDVVAGP MLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYKVGK FPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEMVNEAALALEYGASCEDI ARVCHAHLTLSEAFGEANLAASFGKSINF
Tasks
- Task 2: Multiple Sequence Alignment
- Task 3: odba_human Sequence-based predictions
- Task 4: Homology-based structure prediction
- Task 5: Researching SNPs
- Task 6: MSUD - Sequence-based mutation analysis
- Task 7: MSUD - Structure-based mutation analysis
- Task 8: MSUD - Molecular Dynamics Simulations
- Task 9: MSUD - Normal Mode Analysis
Final Report
The final report will be uploaded here once it is finished.
